|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2002-3-28
|
|
pubmed:abstractText |
Administration of hydroxyurea in sickle cell disease is associated with a dramatic increase of HbF along with a significant clinical improvement and, occasionally, increased total hemoglobin levels. The underlying mechanisms are not yet fully elucidated.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1466-4860
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
1
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
295-300
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:11920206-Adolescent,
pubmed-meshheading:11920206-Adult,
pubmed-meshheading:11920206-Anemia, Sickle Cell,
pubmed-meshheading:11920206-Erythroid Precursor Cells,
pubmed-meshheading:11920206-Erythropoietin,
pubmed-meshheading:11920206-Female,
pubmed-meshheading:11920206-Fetal Hemoglobin,
pubmed-meshheading:11920206-Gene Expression Regulation,
pubmed-meshheading:11920206-Humans,
pubmed-meshheading:11920206-Hydroxyurea,
pubmed-meshheading:11920206-Kidney,
pubmed-meshheading:11920206-Liver,
pubmed-meshheading:11920206-Male,
pubmed-meshheading:11920206-Middle Aged,
pubmed-meshheading:11920206-Sickle Cell Trait,
pubmed-meshheading:11920206-Time Factors,
pubmed-meshheading:11920206-beta-Thalassemia
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Increased erythropoietin level induced by hydroxyurea treatment of sickle cell patients.
|
|
pubmed:affiliation |
Department of Clinical Biochemistry, Aghia Sophia Children's Hospital, 115 27 Athens, Greece.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
